The biowaiver extension for BCS class III drugs: The effect of dissolution rate on the bioequivalence of BCS class III immediate-release drugs predicted by computer simulation

Molecular Pharmaceutics

Volumn 7, Issue 4, 2010, Pages 1235-1243

  Tsume, Yasuhiro ^a   Amidon, Gordon L ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

Author keywords

BCS; cimetidine; dissolution; GastroPlus; permeability; simulation

Indexed keywords

AMOXICILLIN; ATENOLOL; CIMETIDINE; METOPROLOL; PROPRANOLOL;

AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG RELEASE; DRUG SOLUBILITY; GASTROINTESTINAL TRACT; HUMAN; MAXIMUM PLASMA CONCENTRATION; MEMBRANE PERMEABILITY; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; STOMACH EMPTYING;

AMOXICILLIN; ATENOLOL; CELL MEMBRANE PERMEABILITY; CIMETIDINE; COMPUTER SIMULATION; GASTRIC EMPTYING; GASTROINTESTINAL TRACT; HUMANS; METOPROLOL; PHARMACEUTICAL PREPARATIONS; PROPRANOLOL; SOFTWARE;

EID: 77955248335     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp100053q     Document Type: Article

References (40)

1. Kim, J. S.; Mitchell, S.; Kijek, P.; Tsume, Y.; Hilfinger, J.; Amidon, G. L. The suitability of an in situ perfusion model for permeability determinations: utility for BCS class I biowaiver requests Mol. Pharmaceutics 2006, 3 (6) 686-94
2. Oberle, R. L.; Chen, T. S.; Lloyd, C.; Barnett, J. L.; Owyang, C.; Meyer, J.; Amidon, G. L. The influence of the interdigestive migrating myoelectric complex on the gastric emptying of liquids Gastroenterology 1990, 99 (5) 1275-82
3. Guidance for industry: Waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a Biopharmaceutics Classification System; U.S. Department of Health and Human Services, Food and Drug Administration, Center for Evaluation and Research: 2000.
4. DrugBank.
5. Guideline on the investigation of bioequivalence; EMA: 2010.
6. Amidon, G. L.; Lennernas, H.; Shah, V. P.; Crison, J. R. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability Pharm. Res. 1995, 12 (3) 413-20
7. Yazdanian, M.; Briggs, K.; Jankovsky, C.; Hawi, A. The high solubility definition of the current FDA Guidance on Biopharmaceutical Classification System may be too strict for acidic drugs Pharm. Res. 2004, 21 (2) 293-9
8. Kasim, N. A.; Whitehouse, M.; Ramachandran, C.; Bermejo, M.; Lennernas, H.; Hussain, A. S.; Junginger, H. E.; Stavchansky, S. A.; Midha, K. K.; Shah, V. P.; Amidon, G. L. Molecular properties of WHO essential drugs and provisional biopharmaceutical classification Mol. Pharmaceutics 2004, 1 (1) 85-96
9. Takagi, T.; Ramachandran, C.; Bermejo, M.; Yamashita, S.; Yu, L. X.; Amidon, G. L. A provisional biopharmaceutical classification of the top 200 oral drug products in the United States, Great Britain, Spain, and Japan Mol. Pharmaceutics 2006, 3 (6) 631-43
10. Gupta, E.; Barends, D. M.; Yamashita, E.; Lentz, K. A.; Harmsze, A. M.; Shah, V. P.; Dressman, J. B.; Lipper, R. A. Review of global regulations concerning biowaivers for immediate release solid oral dosage forms Eur. J. Pharm. Sci. 2006, 29 (3-'4) 315-24
11. Pade, V.; Stavchansky, S. Estimation of the relative contribution of the transcellular and paracellular pathway to the transport of passively absorbed drugs in the Caco-2 cell culture model Pharm. Res. 1997, 14 (9) 1210-5
12. Martinez, V.; Maguregui, M. I.; Jimenez, R. M.; Alonso, R. M. Determination of the pKa values of beta-blockers by automated potentiometric titrations J. Pharm. Biomed. Anal. 2000, 23 (2-'3) 459-68
13. Riviere, J. E.; Craigmill, A. L.; Sundlof, S. F. Handbook of comparative pharmacokinetics and residues of veterinary antimicrobials; CRC Press, Inc.: Boca Raton, FL, 1991.
14. Davies, N. M. Clinical pharmacokinetics of flurbiprofen and its enantiomers Clin. Pharmacokinet. 1995, 28 (2) 100-14
15. Routledge, P. A.; Shand, D. G. Clinical pharmacokinetics of propranolol Clin. Pharmacokinet. 1979, 4 (2) 73-90
16. Hogstedt, S.; Lindberg, B.; Rane, A. Increased oral clearance of metoprolol in pregnancy Eur. J. Clin. Pharmacol. 1983, 24 (2) 217-20
17. Kortejarvi, H.; Urtti, A.; Yliperttula, M. Pharmacokinetic simulation of biowaiver criteria: the effects of gastric emptying, dissolution, absorption and elimination rates Eur. J. Pharm. Sci. 2007, 30 (2) 155-66
18. Mehvar, R.; Gross, M. E.; Kreamer, R. N. Pharmacokinetics of atenolol enantiomers in humans and rats J. Pharm. Sci. 1990, 79 (10) 881-5
19. Blume, H. H.; Schug, B. S. The Biopharmaceutics classification system (BCS): class III drugs-better candidates for BA/BE waiver Eur. J. Pharm. Sci. 1999, 9 (2) 117-21
20. Cheng, C. L.; Yu, L. X.; Lee, H. L.; Yang, C. Y.; Lue, C. S.; Chou, C. H. Biowaiver extension potential to BCS Class III high solubility-low permeability drugs: bridging evidence for metformin immediate-release tablet Eur. J. Pharm. Sci. 2004, 22 (4) 297-304
21. Yu, L. X.; Amidon, G. L.; Polli, J. E.; Zhao, H.; Mehta, M. U.; Conner, D. P.; Shah, V. P.; Lesko, L. J.; Chen, M. L.; Lee, V. H.; Hussain, A. S. Biopharmaceutics classification system: the scientific basis for biowaiver extensions Pharm. Res. 2002, 19 (7) 921-5
22. Arnal, J.; Gonzalez-Alvarez, I.; Bermejo, M.; Amidon, G. L.; Junginger, H. E.; Kopp, S.; Midha, K. K.; Shah, V. P.; Stavchansky, S.; Dressman, J. B.; Barends, D. M. Biowaiver monographs for immediate release solid oral dosage forms: Aciclovir J. Pharm. Sci. 2008, 97 (12) 5061-73
23. Vogelpoel, H.; Welink, J.; Amidon, G. L.; Junginger, H. E.; Midha, K. K.; Moller, H.; Olling, M.; Shah, V. P.; Barends, D. M. Biowaiver monographs for immediate release solid oral dosage forms based on biopharmaceutics classification system (BCS) literature data: verapamil hydrochloride, propranolol hydrochloride, and atenolol J. Pharm. Sci. 2004, 93 (8) 1945-56
24. Hamacher, J.; Luepke, J.; Reidenberg, B. E.; Nord, C. E.; Borner, K.; Koeppe, P.; Bristol, D.; Lode, H. Changes in fecal flora and comparative multiple-dose pharmacokinetics of Ceftibuten, cefpodoxime proxetil and amoxycillin/clavulanate Clin. Microbiol. Infect. 1999, 5 (6) 339-54
25. Grahnen, A. Cimetidine bioavailability and variable renal clearance Eur. J. Clin. Pharmacol. 1984, 27 (5) 623-4
26. Najib, N. M.; Idkaidek, N.; Adel, A.; Mohammed, B.; Al-Masri, S.; Admour, I.; Alam, S. M.; Dham, R. Qumaruzaman, Comparative bioavailability of two brands of atenolol 100 mg tablets (Tensotin and Tenormin) in healthy human volunteers Biopharm. Drug Dispos. 2005, 26 (1) 1-5
27. Bretschneider, B.; Brandsch, M.; Neubert, R. Intestinal transport of beta-lactam antibiotics: analysis of the affinity at the H+/peptide symporter (PEPT1), the uptake into Caco-2 cell monolayers and the transepithelial flux Pharm. Res. 1999, 16 (1) 55-61
28. Zarowny, D.; Ogilvie, R.; Tamblyn, D.; MacLeod, C.; Ruedy, J. Pharmacokinetics of amoxicillin Clin. Pharmacol. Ther. 1974, 16 (6) 1045-51
29. Li, M.; Anderson, G. D.; Phillips, B. R.; Kong, W.; Shen, D. D.; Wang, J. Interactions of amoxicillin and cefaclor with human renal organic anion and peptide transporters Drug Metab. Dispos. 2006, 34 (4) 547-55
30. Lee, V. H. Membrane transporters Eur. J. Pharm. Sci. 2000, 11 (Suppl. 2) S41-50
31. Wacher, V. J.; Salphati, L.; Benet, L. Z. Active secretion and enterocytic drug metabolism barriers to drug absorption Adv. Drug Delivery Rev. 2001, 46 (1-'3) 89-102 (Pubitemid 33653416)
32. Polli, J. E.; Abrahamsson, B. S.; Yu, L. X.; Amidon, G. L.; Baldoni, J. M.; Cook, J. A.; Fackler, P.; Hartauer, K.; Johnston, G.; Krill, S. L.; Lipper, R. A.; Malick, W. A.; Shah, V. P.; Sun, D.; Winkle, H. N.; Wu, Y.; Zhang, H. Summary workshop report: bioequivalence, biopharmaceutics classification system, and beyond AAPS J. 2008, 10 (2) 373-9
33. Stavchansky, S. Scientific perspectives on extending the provision for waivers of in vivo bioavailability and bioequivalence studies for drug products containing high solubility-low permeability drugs (BCS-Class 3) AAPS J. 2008, 10 (2) 300-5
34. Becker, C.; Dressman, J. B.; Amidon, G. L.; Junginger, H. E.; Kopp, S.; Midha, K. K.; Shah, V. P.; Stavchansky, S.; Barends, D. M. Biowaiver monographs for immediate release solid oral dosage forms: ethambutol dihydrochloride J. Pharm. Sci. 2008, 97 (4) 1350-60
35. Jantratid, E.; Prakongpan, S.; Amidon, G. L.; Dressman, J. B. Feasibility of biowaiver extension to biopharmaceutics classification system class III drug products: cimetidine Clin. Pharmacokinet. 2006, 45 (4) 385-99
36. Jantratid, E.; Prakongpan, S.; Dressman, J. B.; Amidon, G. L.; Junginger, H. E.; Midha, K. K.; Barends, D. M. Biowaiver monographs for immediate release solid oral dosage forms: cimetidine J. Pharm. Sci. 2006, 95 (5) 974-84
37. Kovacevi, I.; Parojci, J.; Tubi-Grozdanis, M.; Langguth, P. An investigation into the importance of very rapid dissolution criteria for drug bioequivalence demonstration using gastrointestinal simulation technology AAPS J. 2009, 11 (2) 381-4
38. Kortejarvi, H.; Shawahna, R.; Koski, A.; Malkki, J.; Ojala, K.; Yliperttula, M. Very rapid dissolution is not needed to guarantee bioequivalence for biopharmaceutics classification system (BCS) I drugs J. Pharm. Sci. 2010, 99 (2) 621-5
39. Kaus, L. C.; Gillespie, W. R.; Hussain, A. S.; Amidon, G. L. The effect of in vivo dissolution, gastric emptying rate, and intestinal transit time on the peak concentration and area-under-the-curve of drugs with different gastrointestinal permeabilities Pharm. Res. 1999, 16 (2) 272-80
40. Koch, K. M.; Parr, A. F.; Tomlinson, J. J.; Sandefer, E. P.; Digenis, G. A.; Donn, K. H.; Powell, J. R. Effect of sodium acid pyrophosphate on ranitidine bioavailability and gastrointestinal transit time Pharm. Res. 1993, 10 (7) 1027-30